title: The effects of luteinizing hormone ablation/replacement versus steroid ablation/replacement on gene expression in the primate corpus luteum.
abstract: This study was designed to provide a genome-wide analysis of the effects of luteinizing hormone (LH) versus steroid ablation/replacement on gene expression in the developed corpus luteum (CL) in primates during the menstrual cycle. On Days 9-11 of the luteal phase, female rhesus monkeys were left untreated (control) or received a GnRH antagonist Antide (A), A + LH, A + LH + the 3beta-hydroxysteroid dehydrogenase inhibitor Trilostane (TRL) or A + LH + TRL + a progestin R5020. On Day 12 of the luteal phase, CL were removed and samples of RNA from individual CL were hybridized to Affymetrix rhesus macaque total genome microarrays. The greatest number of altered transcripts was associated with the ablation/replacement of LH, while steroid ablation/progestin replacement affected fewer transcripts. Replacement of LH during Antide treatment restored the expression of most transcripts to control levels. Validation of a subset of transcripts revealed that the expression patterns were similar between microarray and real-time PCR. Analyses of protein levels were subsequently determined for two transcripts. This is the first genome-wide analysis of LH and steroid regulation of gene transcription in the developed primate CL. Further analysis of novel transcripts identified in this data set can clarify the relative role for LH and steroids in CL maintenance and luteolysis.
authors.affiliation: Oregon National Primate Research Center, Beaverton, 97006, USA. bishopc@ohsu.edu
authors.forename: Cecily V
authors.initials: CV
authors.lastname: Bishop
authors.forename: Jon D
authors.initials: JD
authors.lastname: Hennebold
authors.forename: Richard L
authors.initials: RL
authors.lastname: Stouffer
mesh_terms: D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors; D000818:Animals; D015153:Blotting, Western; D016000:Cluster Analysis; D003338:Corpus Luteum / Q000187:drug effects* / Q000378:metabolism*; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006727:Hormone Antagonists / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology*; D008253:Macaca mulatta; D020411:Oligonucleotide Array Sequence Analysis; D009842:Oligopeptides / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D013256:Steroids / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D006727:Hormone Antagonists; D009842:Oligopeptides; D013256:Steroids; D013196:Dihydrotestosterone; D007986:Luteinizing Hormone; C057022:iturelix; D015096:3-Hydroxysteroid Dehydrogenases; C009954:trilostane